NCT00193531View on ClinicalTrials.gov

Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

December 31, 1998

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions

Neuroendocrine Carcinoma

Interventions

DRUG

Paclitaxel

DRUG

Carboplatin

DRUG

Etoposide

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER